Your browser doesn't support javascript.
loading
Transwell migration assay to interrogate human CAR-T cell chemotaxis.
Oner, Arman; Kobold, Sebastian.
Afiliación
  • Oner A; Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich, Munich, Germany. Electronic address: arman.oener@campus.lmu.de.
  • Kobold S; Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, Research Center for Environmental Health (HMGU), Neuherberg, Germany; German Center for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany. Electronic address: sebastian.kobold@med.uni-muenchen.de.
STAR Protoc ; 3(4): 101708, 2022 12 16.
Article en En | MEDLINE | ID: mdl-36136753
ABSTRACT
A major impediment to effective cellular therapies in solid tumors is the limited access of therapeutic cells to the tumor site. One strategy to overcome this challenge is to endow T cells with chemotactic properties required to access tumor tissue. Here, we present a chimeric antigen receptor (CAR)-modified T cell strategy centered around enhanced T cell trafficking. We outline isolation, activation, and transduction of humancells, as well as techniques for assessing migratory and cytotoxic capacity of CAR-T cells. For complete details on the use and execution of this protocol, please refer to Lesch et al. (2021).
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Neoplasias Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: STAR Protoc Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Neoplasias Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: STAR Protoc Año: 2022 Tipo del documento: Article